1
|
Soeteman-Hernández LG, Blanco CF, Koese M, Sips AJAM, Noorlander CW, Peijnenburg WJGM. Life cycle thinking and safe-and-sustainable-by-design approaches for the battery innovation landscape. iScience 2023; 26:106060. [PMID: 36915691 PMCID: PMC10005908 DOI: 10.1016/j.isci.2023.106060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Developments in battery technology are essential for the energy transition and need to follow the framework for safe-and-sustainable-by-design (SSbD) materials, chemicals, products, and processes as set by the EU. SSbD is a broad approach that ensures that chemicals/advanced materials/products/services are produced and used in a way to avoid harm to humans and the environment. Technical and policy-related literature was surveyed for battery technologies and recommendations were provided for a broad SSbD approach that remains firmly grounded in Life Cycle Thinking principles. The approach integrates functional performance and sustainability (safety, social, environmental, and economic) aspects throughout the life cycle of materials, products, and processes, and evaluates how their interactions reflect on SSbD parameters. 22 different types of batteries were analyzed in a life cycle thinking approach for criticality, toxicity/safety, environmental and social impact, circularity, functionality, and cost to ensure battery innovation has a green and sustainable purpose to avoid unintended consequences.
Collapse
Affiliation(s)
- Lya G Soeteman-Hernández
- National Institute for Public Health and the Environment (RIVM), Center for Safety of Substances and Products, Bilthoven, The Netherlands
| | - Carlos Felipe Blanco
- Institute of Environmental Sciences (CML), Leiden University, P. O. Box 9518, 2300 RA Leiden, The Netherlands
| | - Maarten Koese
- Institute of Environmental Sciences (CML), Leiden University, P. O. Box 9518, 2300 RA Leiden, The Netherlands
| | - Adrienne J A M Sips
- National Institute for Public Health and the Environment (RIVM), Center for Safety of Substances and Products, Bilthoven, The Netherlands
| | - Cornelle W Noorlander
- National Institute for Public Health and the Environment (RIVM), Center for Safety of Substances and Products, Bilthoven, The Netherlands
| | - Willie J G M Peijnenburg
- National Institute for Public Health and the Environment (RIVM), Center for Safety of Substances and Products, Bilthoven, The Netherlands.,Institute of Environmental Sciences (CML), Leiden University, P. O. Box 9518, 2300 RA Leiden, The Netherlands
| |
Collapse
|
2
|
Peijnenburg W, Oomen AG, Soeteman-Hernández LG, Groenewold M, Sips AJAM, Noorlander CW, Kettelarij JAB, Bleeker EAJ. Identification of emerging safety and sustainability issues of advanced materials: Proposal for a systematic approach. NanoImpact 2021; 23:100342. [PMID: 35559843 DOI: 10.1016/j.impact.2021.100342] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Revised: 06/17/2021] [Accepted: 07/06/2021] [Indexed: 06/15/2023]
Abstract
The EU Chemicals Strategy for Sustainability is a first step to achieve the Green Deal ambition for a toxic-free environment, and ensure that chemicals are produced and used in a way that maximises their contribution to society while avoiding harm to our planet and to future generations. Advanced materials are predicted to play a pivotal role in achieving this ambition and the underlying sustainability goals, and considerable efforts are invested in designing new classes of materials. Examples of such materials are metamaterials, artificially architectured materials designed to have material properties beyond those of the individual ingredient materials, or active materials at the boundary between materials and devices (e.g., new biomedical soft materials). Such innovative advanced materials raise concern about possible future safety and sustainability issues and would benefit from appropriate risk governance that promotes innovation, while pushing for safety and sustainability. To balance these aspects, a methodology is proposed for the early-stage identification of emerging safety and sustainability issues of advanced materials. As exemplified by two case studies, the methodology aims to be of use for innovators, risk assessors, and regulators. Extension of the methodology is highlighted, as well as implementation in broader initiatives like the EU's industrial policy approach.
Collapse
Affiliation(s)
- Willie Peijnenburg
- National Institute of Public Health and the Environment (RIVM), Center for the Safety of Substances and Products, PO Box 1, 3720 BA Bilthoven, the Netherlands; Institute of Environmental Sciences (CML), Leiden University, PO Box 9518, 2300 RA Leiden, the Netherlands.
| | - A G Oomen
- National Institute of Public Health and the Environment (RIVM), Center for the Safety of Substances and Products, PO Box 1, 3720 BA Bilthoven, the Netherlands
| | - L G Soeteman-Hernández
- National Institute of Public Health and the Environment (RIVM), Center for the Safety of Substances and Products, PO Box 1, 3720 BA Bilthoven, the Netherlands
| | - M Groenewold
- National Institute of Public Health and the Environment (RIVM), Center for the Safety of Substances and Products, PO Box 1, 3720 BA Bilthoven, the Netherlands
| | - A J A M Sips
- National Institute of Public Health and the Environment (RIVM), Center for the Safety of Substances and Products, PO Box 1, 3720 BA Bilthoven, the Netherlands
| | - C W Noorlander
- National Institute of Public Health and the Environment (RIVM), Center for the Safety of Substances and Products, PO Box 1, 3720 BA Bilthoven, the Netherlands
| | - J A B Kettelarij
- National Institute of Public Health and the Environment (RIVM), Center for the Safety of Substances and Products, PO Box 1, 3720 BA Bilthoven, the Netherlands
| | - E A J Bleeker
- National Institute of Public Health and the Environment (RIVM), Center for the Safety of Substances and Products, PO Box 1, 3720 BA Bilthoven, the Netherlands
| |
Collapse
|
3
|
Soeteman-Hernández LG, Sutcliffe HR, Sluijters T, van Geuns J, Noorlander CW, Sips AJAM. Modernizing innovation governance to meet policy ambitions through trusted environments. NanoImpact 2021; 21:100301. [PMID: 35559788 DOI: 10.1016/j.impact.2021.100301] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Revised: 01/21/2021] [Accepted: 01/22/2021] [Indexed: 06/15/2023]
Abstract
A vision for modernization of nanotechnology innovation governance is a Safe Innovation Approach (SIA). SIA combines two concepts: Safe-by-Design (SbD) and Regulatory Preparedness (RP). SbD aims to motivate industry to integrate safety considerations early in the innovation process and onwards. RP aspires to improve the anticipation capabilities of regulators and develop legislation that can keep pace with innovations. The pace, scope and complexity of nanotechnology present novel challenges for governance, especially law and regulation. A possible option forward for nanotechnology is to move towards a more goal-based governance system including anticipatory regulation. Anticipatory regulation and experimentation can be considered as an agile approach with emphasis on flexibility, collaboration and innovation. SIA can be seen as part of experimentation in support of agile regulatory practices. A trusted environment is needed in which innovators, regulators and other stakeholders are motivated to understand each other's concerns and together develop solutions to anticipate and address safety whilst also facilitating the development of safe, sustainable and socially beneficial innovations. Trust drivers to facilitate trusted environments include focusing on the public interest, competence, respect, integrity, inclusion, fairness and openness. Here, we explore the concept of building trusted environments in the context of the SIA for nanotechnologies.
Collapse
Affiliation(s)
| | | | - Teun Sluijters
- Public Impact, Postbus 97814, 2509 GE, Den Haag, the Netherlands
| | | | - Cornelle W Noorlander
- National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | - Adriënne J A M Sips
- National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| |
Collapse
|
4
|
Brand W, Noorlander CW, Giannakou C, De Jong WH, Kooi MW, Park MV, Vandebriel RJ, Bosselaers IE, Scholl JH, Geertsma RE. Nanomedicinal products: a survey on specific toxicity and side effects. Int J Nanomedicine 2017; 12:6107-6129. [PMID: 28883724 PMCID: PMC5574663 DOI: 10.2147/ijn.s139687] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Due to their specific properties and pharmacokinetics, nanomedicinal products (NMPs) may present different toxicity and side effects compared to non-nanoformulated, conventional medicines. To facilitate the safety assessment of NMPs, we aimed to gain insight into toxic effects specific for NMPs by systematically analyzing the available toxicity data on approved NMPs in the European Union. In addition, by comparing five sets of products with the same active pharmaceutical ingredient (API) in a conventional formulation versus a nanoformulation, we aimed to identify any side effects specific for the nano aspect of NMPs. The objective was to investigate whether specific toxicity could be related to certain structural types of NMPs and whether a nanoformulation of an API altered the nature of side effects of the product in humans compared to a conventional formulation. The survey of toxicity data did not reveal nanospecific toxicity that could be related to certain types of structures of NMPs, other than those reported previously in relation to accumulation of iron nanoparticles (NPs). However, given the limited data for some of the product groups or toxicological end points in the analysis, conclusions with regard to (a lack of) potential nanomedicine-specific effects need to be considered carefully. Results from the comparison of side effects of five sets of drugs (mainly liposomes and/or cytostatics) confirmed the induction of pseudo-allergic responses associated with specific NMPs in the literature, in addition to the side effects common to both nanoformulations and regular formulations, eg, with liposomal doxorubicin, and possibly liposomal daunorubicin. Based on the available data, immunotoxicological effects of certain NMPs cannot be excluded, and we conclude that this end point requires further attention.
Collapse
Affiliation(s)
| | | | - Christina Giannakou
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven.,Department of Toxicogenomics, Maastricht University, Maastricht
| | - Wim H De Jong
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven
| | | | - Margriet Vdz Park
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven
| | - Rob J Vandebriel
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven
| | - Irene Em Bosselaers
- Section Pharmacology, Toxicology and Pharmacokinetics, Medicines Evaluation Board (CBG-MEB), Utrecht
| | - Joep Hg Scholl
- Research & Analysis Department, Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands
| | - Robert E Geertsma
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven
| |
Collapse
|
5
|
Noorlander CW, Kooi MW, Oomen AG, Park MVDZ, Vandebriel RJ, Geertsma RE. Horizon scan of nanomedicinal products. Nanomedicine (Lond) 2015; 10:1599-608. [PMID: 25694061 DOI: 10.2217/nnm.15.21] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
AIM A horizon scan of nanomedicinal product on the market or undergoing clinical investigation by analyzing the current nanomedicinal landscape. MATERIALS & METHODS The horizon scan includes a search of literature, clinical trial registries and the internet. RESULTS This horizon scan yielded 175 nanomedicinal products. Most products were intended for cancer treatment, followed by infectious diseases. Polymer conjugates, liposomes and protein nanoparticles were the most used structures for nanomedicinal products. CONCLUSIONS This paper provides an overview of nanomedicinal products on the market or undergoing clinical investigation, their application areas and specific properties.
Collapse
|
6
|
Noorlander CW, Tijsseling D, Hessel EVS, de Vries WB, Derks JB, Visser GHA, de Graan PNE. Antenatal glucocorticoid treatment affects hippocampal development in mice. PLoS One 2014; 9:e85671. [PMID: 24465645 PMCID: PMC3899077 DOI: 10.1371/journal.pone.0085671] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Accepted: 11/29/2013] [Indexed: 11/18/2022] Open
Abstract
Synthetic glucocorticoids are administered to pregnant women at risk for preterm delivery, to enhance fetal lung maturation. The benefit of this treatment is well established, however caution is necessary because of possible unwanted side effects on development of different organ systems, including the brain. Actions of glucocorticoids are mediated by corticosteroid receptors, which are highly expressed in the hippocampus, a brain structure involved in cognitive functions. Therefore, we analyzed the effects of a single antenatal dexamethasone treatment on the development of the mouse hippocampus. A clinically relevant dose of dexamethasone (0.4 mg/kg) was administered to pregnant mice at embryonic day 15.5 and the hippocampus was analyzed from embryonic day 16 until adulthood. We investigated the effects of dexamethasone treatment on anatomical changes, apoptosis and proliferation in the hippocampus, hippocampal volume and on total body weight. Our results show that dexamethasone treatment reduced body weight and hippocampal volume transiently during development, but these effects were no longer detected at adulthood. Dexamethasone treatment increased the number of apoptotic cells in the hippocampus until birth, but postnatally no effects of dexamethasone treatment on apoptosis were found. During the phase with increased apoptosis, dexamethasone treatment reduced the number of proliferating cells in the subgranular zone of the dentate gyrus. The number of proliferative cells was increased at postnatal day 5 and 10, but was decreased again at the adult stage. This latter long-term and negative effect of antenatal dexamethasone treatment on the number of proliferative cells in the hippocampus may have important implications for hippocampal network function.
Collapse
Affiliation(s)
- Cornelle W. Noorlander
- Brain Center Rudolf Magnus, Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Utrecht, The Netherlands
- Department of Obstetrics, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Deodata Tijsseling
- Department of Obstetrics, University Medical Center Utrecht, Utrecht, The Netherlands
- * E-mail:
| | - Ellen V. S. Hessel
- Brain Center Rudolf Magnus, Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Willem B. de Vries
- Department of Neonatology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Jan B. Derks
- Department of Obstetrics, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Gerard H. A. Visser
- Department of Obstetrics, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Pierre N. E. de Graan
- Brain Center Rudolf Magnus, Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Utrecht, The Netherlands
| |
Collapse
|
7
|
Smit-Rigter LA, Noorlander CW, von Oerthel L, Chameau P, Smidt MP, van Hooft JA. Prenatal fluoxetine exposure induces life-long serotonin 5-HT3 receptor-dependent cortical abnormalities and anxiety-like behaviour. Neuropharmacology 2012; 62:865-70. [DOI: 10.1016/j.neuropharm.2011.09.015] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2011] [Revised: 09/13/2011] [Accepted: 09/14/2011] [Indexed: 10/17/2022]
|
8
|
Noorlander CW, van Leeuwen SPJ, Te Biesebeek JD, Mengelers MJB, Zeilmaker MJ. Levels of perfluorinated compounds in food and dietary intake of PFOS and PFOA in the Netherlands. J Agric Food Chem 2011; 59:7496-505. [PMID: 21591675 DOI: 10.1021/jf104943p] [Citation(s) in RCA: 174] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
This study presents concentrations of perfluorinated compounds in food and the dietary intake of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in The Netherlands. The concentrations of perfluorinated compounds in food were analyzed in pooled samples of foodstuffs randomly purchased in several Dutch retail store chains with nation-wide coverage. The concentrations analyzed for PFOS and PFOA were used to assess the exposure to these compounds in The Netherlands. As concentrations in drinking water in The Netherlands were missing for these compounds, conservative default concentrations of 7 pg/g for PFOS and 9 pg/g for PFOA, as reported by European Food Safety Authority, were used in the exposure assessment. In food, 6 out of 14 analyzed perfluorinated compounds could be quantified in the majority of the food categories (perfluoroheptanoic acid (PFHpA), PFOA, perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA), perfluoro-1-hexanesulfonate (PFHxS), and PFOS). The highest concentration of the sum of these six compounds was found in crustaceans (825 pg/g product, PFOS: 582 pg/g product) and in lean fish (481 pg/g product, PFOS: 308 pg/g product). Lower concentrations were found in beef, fatty fish, flour, butter, eggs, and cheese (concentrations between 20 and 100 pg/g product; PFOS, 29-82 pg/g product) and milk, pork, bakery products, chicken, vegetable, and industrial oils (concentration lower than 10 pg/g product; PFOS not detected). The median long-term intake for PFOS was 0.3 ng/kg bw/day and for PFOA 0.2 ng/kg bw/day. The corresponding high level intakes (99th percentile) were 0.6 and 0.5 ng/kg bw/day, respectively. These intakes were well below the tolerable daily intake values of both compounds (PFOS, 150 ng/kg bw/day; PFOA, 1500 ng/kg bw/day). The intake calculations quantified the contribution of drinking water to the PFOS and PFOA intake in The Netherlands. Important contributors of PFOA intake were vegetables/fruit and flour. Milk, beef, and lean fish were important contributors of PFOS intake.
Collapse
Affiliation(s)
- Cornelle W Noorlander
- Centre for Substances and Integral Risk Assessment, National Institute for Public Health and the Environment, BA, Bilthoven, The Netherlands.
| | | | | | | | | |
Collapse
|
9
|
Noorlander CW, Ververs FFT, Nikkels PGJ, van Echteld CJA, Visser GHA, Smidt MP. Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. PLoS One 2008; 3:e2782. [PMID: 18716672 PMCID: PMC2518512 DOI: 10.1371/journal.pone.0002782] [Citation(s) in RCA: 127] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2008] [Accepted: 07/01/2008] [Indexed: 11/19/2022] Open
Abstract
Background Women are at great risk for mood and anxiety disorders during their childbearing years and may become pregnant while taking antidepressant drugs. In the treatment of depression and anxiety disorders, selective serotonin reuptake inhibitors (SSRIs) are the most frequently prescribed drugs, while it is largely unknown whether this medication affects the development of the central nervous system of the fetus. The possible effects are the product of placental transfer efficiency, time of administration and dose of the respective SSRI. Methodology/Principal Findings In order to attain this information we have setup a study in which these parameters were measured and the consequences in terms of physiology and behavior are mapped. The placental transfer of fluoxetine and fluvoxamine, two commonly used SSRIs, was similar between mouse and human, indicating that the fetal exposure of these SSRIs in mice is comparable with the human situation. Fluvoxamine displayed a relatively low placental transfer, while fluoxetine showed a relatively high placental transfer. Using clinical doses of fluoxetine the mortality of the offspring increased dramatically, whereas the mortality was unaffected after fluvoxamine exposure. The majority of the fluoxetine-exposed offspring died postnatally of severe heart failure caused by dilated cardiomyopathy. Molecular analysis of fluoxetine-exposed offspring showed long-term alterations in serotonin transporter levels in the raphe nucleus. Furthermore, prenatal fluoxetine exposure resulted in depressive- and anxiety-related behavior in adult mice. In contrast, fluvoxamine-exposed mice did not show alterations in behavior and serotonin transporter levels. Decreasing the dose of fluoxetine resulted in higher survival rates and less dramatic effects on the long-term behavior in the offspring. Conclusions These results indicate that prenatal fluoxetine exposure affects fetal development, resulting in cardiomyopathy and a higher vulnerability to affective disorders in a dose-dependent manner.
Collapse
Affiliation(s)
- Cornelle W. Noorlander
- Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Utrecht, The Netherlands
| | | | - Peter G. J. Nikkels
- Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
| | | | - Gerard H. A. Visser
- Department of Obstetrics, Neonatology and Gynaecology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Marten P. Smidt
- Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Utrecht, The Netherlands
- * E-mail:
| |
Collapse
|
10
|
Smits SM, Noorlander CW, Kas MJH, Ramakers GMJ, Smidt MP. Alterations in serotonin signalling are involved in the hyperactivity of Pitx3-deficient mice. Eur J Neurosci 2008; 27:388-95. [PMID: 18215235 DOI: 10.1111/j.1460-9568.2008.06032.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Pitx3 deficiency in mice causes a dramatic loss of dopaminergic neurones located in the substantia nigra pars compacta during development. This early disruption of the nigrostriatal pathway in Pitx3-deficient mice is characterized by increased spontaneous home-cage activity levels during the habitual sleep phase of these animals. These findings are reminiscent of the spontaneous hyperactivity in mice neonatally lesioned with 6-hydroxydopamine, which is caused by an extensive serotonergic hyperinnervation of the striatum. The present study investigated whether an imbalance between dopamine (DA) and serotonin (5-HT) signalling is involved in the behavioural phenotype of Pitx3-deficient mice. Serotonergic hyperinnervation was demonstrated by increased [3H]-citalopram autoradiographic binding specifically in the dorsal striatum of adult Pitx3-deficient mice, indicating alterations in 5-HT transporter levels that correlated to DA dysfunction in Pitx3 deficiency. In addition, stimulus-induced release of DA and 5-HT indicated an altered balance between these neurotransmitters in the dorsal striatum of Pitx3-/- mice. To determine whether the increased 5-HT signalling was involved in the spontaneous hyperactivity during the light phase observed in Pitx3 deficiency, we treated Pitx3-deficient and control mice with the selective irreversible tryptophan hydroxylase inhibitor p-chlorophenylalanine to decrease 5-HT levels. Reduction of 5-HT levels in Pitx3-deficient mice decreased their locomotor activity to normal levels, whereas the same treatment increased the locomotor activity levels of control mice. Taken together, our results indicate alterations in 5-HT signalling in Pitx3-deficient mice that underlie their spontaneous hyperactivity.
Collapse
Affiliation(s)
- Simone M Smits
- Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands.
| | | | | | | | | |
Collapse
|
11
|
Jacobs FMJ, Smits SM, Noorlander CW, von Oerthel L, van der Linden AJA, Burbach JPH, Smidt MP. Retinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency. Development 2007; 134:2673-84. [PMID: 17592014 DOI: 10.1242/dev.02865] [Citation(s) in RCA: 109] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Selective neuronal loss in the substantia nigra (SNc), as described for Parkinson's disease (PD) in humans and for Pitx3 deficiency in mice, highlights the existence of neuronal subpopulations. As yet unknown subset-specific gene cascades might underlie the observed differences in neuronal vulnerability. We identified a developmental cascade in mice in which Ahd2 (Aldh1a1) is under the transcriptional control of Pitx3. Interestingly, Ahd2 distribution is restricted to a subpopulation of the meso-diencephalic dopaminergic (mdDA) neurons that is affected by Pitx3 deficiency. Ahd2 is involved in the synthesis of retinoic acid (RA), which has a crucial role in neuronal patterning, differentiation and survival in the brain. Most intriguingly, restoring RA signaling in the embryonic mdDA area counteracts the developmental defects caused by Pitx3 deficiency. The number of tyrosine hydroxylase-positive (TH+) neurons was significantly increased after RA treatment in the rostral mdDA region of Pitx3-/- embryos. This effect was specific for the rostral part of the developing mdDA area, and was observed exclusively in Pitx3-/- embryos. The effect of RA treatment during the critical phase was preserved until later in development, and our data suggest that RA is required for the establishment of proper mdDA neuronal identity. This positions Pitx3 centrally in a mdDA developmental cascade linked to RA signaling. Here, we propose a novel mechanism in which RA is involved in mdDA neuronal development and maintenance, providing new insights into subset-specific vulnerability in PD.
Collapse
Affiliation(s)
- Frank M J Jacobs
- Rudolf Magnus Institute of Neuroscience, Department of Pharmacology and Anatomy, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
12
|
Noorlander CW, De Graan PNE, Middeldorp J, Van Beers JJBC, Visser GHA. Ontogeny of hippocampal corticosteroid receptors: Effects of antenatal glucocorticoids in human and mouse. J Comp Neurol 2006; 499:924-32. [PMID: 17072842 DOI: 10.1002/cne.21162] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Women at risk for preterm delivery are treated with synthetic glucocorticoids (GCs) to enhance fetal lung maturation. GCs can bind to two intracellular receptors, the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR), which function as transcription factors. Both are highly expressed in the hippocampus. Several studies have focused on adverse side effects of antenatal GC treatment. However, relatively little is known about the ontogeny of GR and MR, especially in human. Therefore, we studied the ontogeny of both receptors in the human and mouse hippocampus and investigated the effects of antenatal dexamethasone (dex) treatment, a synthetic glucocorticoid, on MR and GR mRNA levels during hippocampal development. The results demonstrate that MR mRNA was first expressed in mouse hippocampus at embryonic day (E)15.5, at the timepoint when dex was administered. In contrast, GR mRNA expression was first observed after birth at postnatal day (P)5. However, in the human hippocampus both receptors are expressed at 24 weeks of gestation, when antenatal GCs are administered in clinical practice. Quantitative in situ hybridization demonstrated that MR mRNA levels were reduced only shortly after dex treatment at E16, but were unaffected from E18 onwards. These findings indicate that a single antenatal dex administration at E15.5 transiently affects MR mRNA levels in the mouse hippocampus. No effect of antenatal dex treatment was found on the human hippocampus at the third trimester of pregnancy. These data on the prenatal ontogeny of both corticosteroid receptors in the human hippocampus is important for understanding the significance of fetal glucocorticoid or stress exposure and its potential effects on health and disease.
Collapse
Affiliation(s)
- C W Noorlander
- Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, 3584 CG Utrecht, The Netherlands.
| | | | | | | | | |
Collapse
|
13
|
Noorlander CW, de Graan PNE, Nikkels PGJ, Schrama LH, Visser GHA. Distribution of Glutamate Transporters in the Human Placenta. Placenta 2004; 25:489-95. [PMID: 15135231 DOI: 10.1016/j.placenta.2003.10.018] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2003] [Revised: 10/22/2003] [Accepted: 10/24/2003] [Indexed: 11/13/2022]
Abstract
Glutamate metabolism is known to be important for growth and development of the human fetus. The glutamate transporters EAAT1, EAAT2 and EAAT3 are key components of the glutamate-glutamine cycle and responsible for active transport of glutamate over the cell membrane. The placenta is thought to regulate glutamate transport during fetal development. Glutamate transporters have been found in placentae of rats, but their distribution in the human placenta is unknown. Therefore, the distribution of glutamate transporters EAAT1, EAAT2 and EAAT3 were analysed in the human placenta during normal pregnancies ending between 8 and 40 weeks of gestation and in placentae of intrauterine growth restricted infants with gestational ages between 28 and 35 weeks of pregnancy. Using immunohistochemistry, EAAT1 expression was found in the syncytiotrophoblast layer, while EAAT2 was detected in the syncytiotrophoblast layer and in endothelial cells of about 5 per cent of all fetal blood vessels. EAAT3 was observed in the endothelium of the fetal blood vessels in all placentae examined. However, expression was also found in the syncytio- and the cytotrophoblast layer of the fetal villi at 8 weeks of gestational age. The expression patterns of EAAT1, EAAT2 and EAAT3 suggest involvement in active transport of glutamate between the fetal and maternal blood circulation. No differences were found in the distribution of the glutamate transporters between control and IUGR placentae. Our data show specific localization of EAAT1, EAAT2 and EAAT3 in the human placenta during development.
Collapse
Affiliation(s)
- C W Noorlander
- Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands
| | | | | | | | | |
Collapse
|
14
|
Abstract
Determination of S-100 a and b and neuron-specific enolase (NSE) in (cord) blood and amniotic fluid has been used to assess neonatal neuronal damage after compromising conditions. However, these proteins are not only found in nervous tissue, and their expression in placenta and umbilical cord has never been investigated. In this study, S-100 (a and b) and NSE expression in human cord and placental tissue was studied by immunohistochemical analysis. Similar analysis was performed using two other brain-specific markers: glial fibrillary acidic protein and growth-associated protein B-50 (also known as GAP-43 or neuromodulin). Tissue was derived after elective cesarean section in seven women of different gestational ages after uncomplicated or complicated pregnancy. S-100 a and b and NSE immunoreactivity was found in several cell types and structures in the umbilical cord as well as in the placenta of all seven cases. Glial fibrillary acidic protein and B-50 showed no immunoreactivity. These data are of importance for interpreting findings of studies in which S-100 or NSE levels in cord blood or amniotic fluid have been related to neuronal damage in the neonate. The increased levels found may just as well be caused by leakage from placenta or umbilical cord as be caused by brain damage. We conclude that S-100 a and b and NSE are not suitable markers for neonatal brain damage. Brain-restricted proteins such as glial fibrillary acidic protein and B-50 seem more promising.
Collapse
Affiliation(s)
- Lia D E Wijnberger
- Department of Obstetrics, University Medical Center Utrecht, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|